KIN

Kindred Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.930
-0.090
-2.24%
After Hours: 3.930 0 0.00% 16:00 10/27 EDT
OPEN
4.020
PREV CLOSE
4.020
HIGH
4.060
LOW
3.900
VOLUME
169.73K
TURNOVER
--
52 WEEK HIGH
11.93
52 WEEK LOW
3.105
MARKET CAP
154.72M
P/E (TTM)
-5.0573
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kindred Shares Up on Expansion of Agreement With Vaxart
Kindred (KIN) expands an agreement with Vaxart for the manufacturing of the latter's oral vaccine for COVID-19 and other vaccine candidates.
Zacks · 10/08 16:37
Vaxart and Kindred Bio expand manufacturing agreement for COVID-19 vaccine candidates
Vaxart (VXRT) and Centaur Biopharmaceutical Services, a subsidiary of Kindred Biosciences (KIN) have expanded their agreement under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and other vaccine candidates.
Seekingalpha · 10/07 12:21
Kindrid Biosciences Subsidiary Centaur Announces Expansion Of Manufacturing Agreement With Vaxart For Coronavirus And Other Vaccine Candidates
Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates SAN FRANCISCO, Oct. 7, 2020 /PRNewswire/ -- Centaur Biopharmaceutical
Benzinga · 10/07 12:05
Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
Centaur Biopharmaceutical Services Inc. (Centaur), a wholly-owned subsidiary of Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), today announced an expanded agreement between KindredBio and Vaxart, Inc. (Nasdaq: VXRT) under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and
PR Newswire · 10/07 12:02
SpringWorks Inks Deal With Pfizer for Nirogacestat Combo
SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.
Zacks · 10/06 17:50
Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session
Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zacks · 10/06 13:48
What Kind Of Shareholders Hold The Majority In Kindred Biosciences, Inc.'s (NASDAQ:KIN) Shares?
If you want to know who really controls Kindred Biosciences, Inc. (NASDAQ:KIN), then you'll have to look at the makeup...
Simply Wall St. · 09/28 14:28
Why Kindred Biosciences Is Trading Higher Today
Kindred Biosciences (NASDAQ: KIN) shares are trading higher on Wednesday after the company announced results from a pivotal efficacy study of parvovirus monoclonal antibody. Results showed 100% efficacy in the prevention of parvovirus, as well as a mortality benefit.
Benzinga · 09/16 18:57
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KIN. Analyze the recent business situations of Kindred Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KIN stock price target is 11.64 with a high estimate of 14.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 27.57M
% Owned: 70.04%
Shares Outstanding: 39.37M
TypeInstitutionsShares
Increased
36
1.63M
New
30
837.54K
Decreased
16
2.61M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.40%
Pharmaceuticals & Medical Research
-0.74%
Key Executives
President/Chief Executive Officer/Director
Richard Chin
Chief Financial Officer/Secretary
Wendy Wee
Chief Scientific Officer
Hangjun Zhan
Director
Denise Bevers
Independent Director
Ernest Mario
Independent Director
Ernie Mario
Independent Director
Joseph McCracken
Independent Director
Herbert Montgomery
Independent Director
Raymond Townsend
Independent Director
Ervin Veszpremi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kindred Biosciences Inc stock information, including NASDAQ:KIN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KIN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KIN stock methods without spending real money on the virtual paper trading platform.